Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navtemadlin + Radiotherapy in Soft Tissue Sarcoma
NCT03217266Phase 1Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2018
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navtemadlin in soft tissue sarcoma (STS) (3 arms), sponsored by National Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 10 weeks and Dose-Limiting Toxicities at 10 weeks. Started Jun 2018; status: completed.
02
Drugs
navtemadlin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03217266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03217266.